GE Healthcare has highlighted an innovative portfolio of molecular imaging technologies and agents at the 57th annual meeting of the Society of Nuclear Medicine (SNM). One example of how GE Healthcare has improved clinician’s experience for patients is through dose management. Another example of GE Healthcare’s commitment to responsible dose management is the ability to reduce injected dose by up to 50 percent compared with standard cardiac and bone protocols.

Read the full story here

The United States Food and Drug Administration has given the marketing clearance to Imaging Therapeutics’ OsDx™ Hip Bone Mineral Density (BMD) system. Designed to estimate the BMD of the proximal femur with the use of standard antero-posterior hip or pelvis radiographic images, the stand-alone X-ray image-processing software will assist physicians in assessing osteoporosis. The system will help in making BMD testing more accessible. Earlier detection will facilitate early drug intervention to treat fractures.